Regulus Therapeutics (RGLS) Issues Encouraging Update from RG-101 Phase 2 in HCV; Plans Accelerated Development
Tweet Send to a Friend
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced interim results from one of the company's ongoing Phase II studies of RG-101 for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
